Immune reset: CAR-T therapy targets lupus, MS, and more
NCT ID NCT06775912
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new treatment called RD06-05, which uses a patient's own immune cells modified to target and reset the immune system in autoimmune diseases like lupus, multiple sclerosis, and vasculitis. The goal is to check safety and how well the body tolerates it. Up to 18 adults aged 18–70 with active disease will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANCA ASSOCIATED VASCULITIS (AAV) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First People's Hospital of Lianyungang
RECRUITINGLianyungang, Jiangus, 222000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we decode the different types of pain in multiple sclerosis?
- Can a blood pressure pill slow MS disability?
- Hidden MS progression: can brain scans and blood tests predict it?
- Can Brain-Training apps fix sleep in MS?
- Can an Iron-Based dye reveal hidden inflammation in progressive MS?
- A simple blood test may reveal kidney damage in lupus — no biopsy needed?